Millennium Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Millennium Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$1.15M	–	6648
2023 Q3	$1.15M	Buy	100,000 +62,700	+168%	+$1.21M	﹤0.01%	4084
2023 Q2	$944K	Buy	+37,300	New	+$1.16M	﹤0.01%	4089
2022 Q4	–	Sell	-29,900	Closed	-$807K	–	7172
2022 Q3	$807K	Buy	+29,900	New	+$607K	﹤0.01%	4523
2020 Q4	–	Sell	-25,000	Closed	-$629	–	5673
2020 Q3	$629	Buy	+25,000	New	+$655K	﹤0.01%	3451
2019 Q4	–	Sell	-39,400	Closed	-$512K	–	4705
2019 Q3	$512K	Buy	+39,400	New	+$482K	﹤0.01%	3243
2018 Q1	–	Sell	-100,000	Closed	-$3.58M	–	4170
2017 Q4	$3.58M	Buy	+100,000	New	+$2.87M	﹤0.01%	1926

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Millennium Management's RVNC Position: Q1 2025 in Review

Millennium Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,551,372 shares — an estimated $4.72M sold.

Millennium Management first reported a position in RVNC in Q1 2014 and held it in 34 quarters. The position peaked at $46M in Q1 2018. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Millennium Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Millennium Management sold 1,551,372 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.72M.
Millennium Management first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 34 quarters.
Millennium Management's Revance Therapeutics, Inc. position peaked at $46M in Q1 2018.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Millennium Management's 13F filing for Q1 2025, filed 15 May 2025.